United States securities and exchange commission logo





                               July 10, 2023

       Yi Larson
       Chief Financial Officer
       LianBio
       103 Carnegie Center Drive, Suite 309
       Princeton, NJ 08540

                                                        Re: LianBio
                                                            Form 10-K for
Fiscal Year Ended December 31, 2022
                                                            Filed March 28,
2023
                                                            File No. 001-40947

       Dear Yi Larson:

              We have reviewed your filing and have the following comments. In
some of our
       comments, we may ask you to provide us with information so we may better
understand your
       disclosure.

              Please respond to these comments within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comments apply to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to these comments, we may have additional comments.

       Form 10-K for Fiscal Year Ended December 31, 2022

       Part 1
       Item 1. Business, page 8

   1.                                                   In future filings,
please disclose prominently at the onset of Part I that you are not a
                                                        Chinese operating
company but a Cayman Islands holding company with operations
                                                        conducted by your
subsidiaries.
       Management's Discussion and Analysis of Financial Condition and Results
of Operations, page
       175

   2.                                                   You disclose on page
185 that you "monitor research and development expenses directly
                                                        associated with (y)our
clinical assets at the program level to some degree, however,
                                                        indirect costs
associated with clinical development and the balance of our research and
                                                        development expenses
are not tracked at the program or candidate level." Further, it
                                                        appears you have
experienced a significant increase in your CRO costs since the periods
 Yi Larson
LianBio
July 10, 2023
Page 2
         presented in your initial registration statement, such that separate
disclosure is warranted
         at this point. For the portion of your CRO costs presented in your
table on page 179 that
         you do track on a program or product candidate basis, revise your
future filings to
         separately quantify those amounts by program or product candidate.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

        You may contact Tracie Mariner, Staff Accountant, at (202) 551-3744 or
Kevin Vaughn,
Accounting Branch Chief, at (202) 551-3494 if you have questions regarding
comments on the
financial statements and related matters. Please contact Jimmy McNamara, Staff
Attorney, at
(202) 551-7349 or Joe McCann, Legal Branch Chief, with any other questions.



FirstName LastNameYi Larson                                     Sincerely,
Comapany NameLianBio
                                                                Division of
Corporation Finance
July 10, 2023 Page 2                                            Office of Life
Sciences
FirstName LastName